"Metabolic Diseases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Descriptor ID |
D008659
|
| MeSH Number(s) |
C18.452
|
| Concept/Terms |
Metabolic Diseases- Metabolic Diseases
- Thesaurismosis
- Thesaurismoses
- Diseases, Metabolic
- Disease, Metabolic
- Metabolic Disease
|
Below are MeSH descriptors whose meaning is more general than "Metabolic Diseases".
Below are MeSH descriptors whose meaning is more specific than "Metabolic Diseases".
This graph shows the total number of publications written about "Metabolic Diseases" by people in this website by year, and whether "Metabolic Diseases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 4 | 1 | 5 |
| 2019 | 2 | 2 | 4 |
| 2020 | 0 | 1 | 1 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 4 | 0 | 4 |
| 2024 | 3 | 0 | 3 |
| 2025 | 6 | 0 | 6 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metabolic Diseases" by people in Profiles.
-
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics. Aliment Pharmacol Ther. 2026 Nov; 64(9):1184-1196.
-
Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis. Med. 2026 May 08; 7(5):101077.
-
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study. Lancet Gastroenterol Hepatol. 2026 Mar; 11(3):232-242.
-
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025 11; 10(11):998-1012.
-
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):633-645.e4.
-
Risk of longer-term endocrine and metabolic conditions in the Deepwater Horizon Oil Spill Coast Guard cohort study - five years of follow-up. Environ Health. 2025 03 22; 24(1):12.
-
Reactive Oxygen Species (ROS) in Metabolic Disease-Don't Shoot the Metabolic Messenger. Int J Mol Sci. 2025 Mar 14; 26(6).
-
Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 06; 11(1):14.
-
Consensus on the key characteristics of metabolism disruptors. Nat Rev Endocrinol. 2025 Apr; 21(4):245-261.
-
Variance Between Clinical Guidance and Real-World Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):374-376.e3.